Correlation between cephamycin consumption and the incidence of antimicrobial resistance in Acinetobacter baumannii at a university hospital in China from 2001 to 2009

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 12, 2011, Pages 765-771

  Song, W ^a   Cao, J ^a   Mei, Y L ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

A. Baumannii; Antimicrobial resistance; Cephamycin consumption

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFMETAZOLE; CEFMINOX; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEPHAMYCIN; CILASTATIN PLUS IMIPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CHINA; COMPUTER PROGRAM; CONTROLLED STUDY; CROSS RESISTANCE; DRUG CLASSIFICATION; DRUG USE; MULTIDRUG RESISTANCE; NONHUMAN; PRESCRIPTION; RETROSPECTIVE STUDY; TREND STUDY; UNIVERSITY HOSPITAL;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; CEPHAMYCINS; CHINA; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; TIME FACTORS;

EID: 82655173706     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201595     Document Type: Article

References (28)

1. Iosifidis E, Antachopoulos C, Tsivitanidou M, Katragkou A, Farmaki E, Tsiakou M, Kyriazi T, Sofianou D, Roilides E. Differential correlation between rates of antimicrobial drug consumption and prevalence of antimicrobial resistance in a tertiary care hospital in Greece. Infect Control Hosp Epidemiol. 2008; 29: 615-622. doi:10.1086/589333 PubMed (Pubitemid 352009386)
2. Koulenti D, Lisboa T, Brun-Buisson C, Krueger W, Macor A, Sole-Violan J, Diaz E, Topeli A, DeWaele J, Carneiro A, Martin-Loeches I, Armaganidis A, Rello J; EU-VAP/CAP Study Group. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit Care Med. 2009; 37: 2360-2369. doi:10.1097/CCM.0b013e3181a037ac PubMed
3. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008; 21: 538-582. doi:10.1128/CMR.00058-07 PubMed
4. 2008 Annual report on implementation of the action plan at http://www.cdc.gov/drugresistance/annualReports.html.
5. Xiao YH, Wang J, Li Y; MOH National Antimicrobial Resistance Investigation Net. Bacterial resistance surveillance in China: a report from Mohnarin 2004 - 2005. Eur J Clin Microbiol Infect Dis. 2008; 27: 697-708. doi:10.1007/s10096-008-0494-6 PubMed
6. Mak JK, Kim MJ, Pham J, Tapsall J, White PA. Antibiotic resistance determinants in nosocomial strains of multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2009; 63: 47-54. doi:10.1093/jac/dkn454 PubMed
7. Valencia R, Arroyo LA, Conde M, Aldana JM, Torres MJ, Fernández-Cuenca F, Garnacho-Montero J, Cisneros JM, Ortíz C, Pachón J, Aznar J. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol. 2009; 30: 257-263. doi:10.1086/595977 PubMed
8. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis. 2000; 31: 101-106. doi:10.1086/313902 PubMed (Pubitemid 32268946)
9. Kuo LC, Teng LJ, Yu CJ, Ho SW, Hsueh PR. Dissemination of a clone of unusual phenotype of pandrug-resistant Acinetobacter baumannii at a university hospital in Taiwan. J Clin Microbiol. 2004; 42: 1759-1763. doi:10.1128/JCM.42.4. 1759-1763.2004 PubMed
10. Lerma M, Cebrián L, Giménez M, Coronel P, Gimeno M, Aguilar L, García de Lomas J. b-lactam susceptibility of Escherichia coli isolates from urinary tract infections exhibiting different resistance phenotypes. Rev Esp Quimioter. 2008; 21: 149-152. PubMed
11. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type b-lactamases. Antimicrob Agents Chemother. 2002; 46: 1-11. doi:10.1128/AAC.46.1. 1-11.2002 PubMed
12. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 16th informational supplement. Wayne, PA: CLSI, 2006:M100-S16.
13. Natsch S, Hekster YA, de Jong R, Heerdink ER, Herings RM, van der Meer JW. Application of the ATC/DDD methodology to monitor antibiotic drug use. Eur J Clin Microbiol Infect Dis. 1998; 17: 20-24. doi:10.1007/BF01584358 PubMed (Pubitemid 28072284)
14. Jacoby GA. AmpC b-lactamases. Clin Microbiol Rev. 2009; 22: 161-182. doi:10.1128/CMR.00036-08 PubMed
15. Ganzhu FENG, Yang ZHANG, Kun YAO, Shuidi ZHAO. AmpC enzyme genes and b-lactamases genes for multi-resistant Acinetobacter baumannnii in Nanjing. Chin J Nosocomiol. 2008; 18: 1364-1367.
16. Chen CH, Young TG, Huang CC. Predictive biomarkers for drug-resistant Acinetobacter baumannii isolates with bla(TEM-1), AmpC-type bla and integrase 1 genotypes. J Microbiol Immunol Infect. 2006; 39: 372-379. PubMed (Pubitemid 46050706)
17. PER-1 gene in gram-negative bacteria. Antimicrob Agents Chemother. 2005; 49: 1708-1713. doi:10.1128/AAC.49.5.1708-1713.2005 PubMed
18. Poirel L, Menuteau O, Agoli N, Cattoen C, Nordmann P. Outbreak of extended-spectrum b-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol. 2003; 41: 3542-3547. doi:10.1128/JCM.41.8.3542-3547.2003 PubMed (Pubitemid 36994680)
19. Naas T, Bogaerts P, Bauraing C, Degheldre Y, Glupczynski Y, Nordmann P. Emergence of PER and VEB extended-spectrum beta-lactamases in Acinetobacter baumannii in Belgium. J Antimicrob Chemother. 2006; 58: 178-182. doi:10.1093/jac/dkl178 PubMed (Pubitemid 44295003)
20. Corvec S, Poirel L, Naas T, Drugeon H, Nordmann P. Genetics and expression of the carbapenemhydrolyzing oxacillinase gene blaOXA-23 in Acinetobacter baumannii. Antimicrob Agents Chemother. 2007; 51: 1530-1533. doi:10.1128/AAC.01132-06 PubMed (Pubitemid 46586845)
21. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006; 12: 826-836. doi:10.1111/j.1469-0691.2006.01456.x PubMed (Pubitemid 44151282)
22. Takahashi A, Yomoda S, Kobayashi I, Okubo T, Tsunoda M, Iyobe S. Detection of carbapenemase-producing Acinetobacter baumannii in a hospital. J Clin Microbiol. 2000; 38: 526-529. PubMed (Pubitemid 30082635)
23. Nemec A, Dolzani L, Brisse S, van den Broek P, Dijkshoorn L. Diversity of aminoglycoside-resistance genes and their association with class 1 integrons among strains of pan-European Acinetobacter baumannii clones. J Med Microbiol. 2004; 53: 1233-1240. doi:10.1099/jmm.0.45716-0 PubMed (Pubitemid 40052479)
24. Doi Y, Adams JM, Yamane K, Paterson DL. Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. Antimicrob Agents Chemother. 2007; 51: 4209-4210. doi:10.1128/AAC.00560-07 PubMed (Pubitemid 350057832)
25. Boo TW, Walsh F, Crowley B. Molecular characterization of carbapenem-resistant Acinetobacter species in an Irish university hospital: predominance of Acinetobacter genomic species 3. J Med Microbiol. 2009; 58: 209-216. doi:10.1099/jmm.0.004911-0 PubMed
26. Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, Richet H, Robert C, Mangenot S, Abergel C, Nordmann P, Weissenbach J, Raoult D, Claverie JM. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet. 2006; 2: e7. doi:10.1371/journal.pgen.0020007 PubMed
27. Gu B, Tong M, Zhao W, Liu G, Ning M, Pan S, Zhao W. Prevalence and characterization of class I integrons among Pseudomonas aeruginosa and Acinetobacter baumannii isolates from patients in Nanjing, China. J Clin Microbiol. 2007; 45: 241-243. doi:10.1128/JCM.01318-06 PubMed (Pubitemid 46106436)
28. Ganzhu FENG, Yang ZHANG, Shuidi ZHAO. The genetic feature of a strain of pan-drug resistant Acinetobacter baumannii. Chin J Clin Infect Dis. 2009; 2: 288-292.